공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

피라진아미드(Pyrazinamide) 시장 규모 : 환자 유형, 유통채널, 지역 - 점유율, 전망, 기회 분석(2020-2027년)

Pyrazinamide Market, by Patient Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

리서치사 Coherent Market Insights
발행일 2020년 12월 상품 코드 980002
페이지 정보 영문
가격
US $ 4,500 ₩ 5,086,000 PPT Turned PDF (Single User License)
US $ 7,000 ₩ 7,912,000 PPT Turned PDF (Multi-user License)
US $ 10,000 ₩ 11,303,000 PPT Turned PDF (Enterprise User License)


피라진아미드(Pyrazinamide) 시장 규모 : 환자 유형, 유통채널, 지역 - 점유율, 전망, 기회 분석(2020-2027년) Pyrazinamide Market, by Patient Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
발행일 : 2020년 12월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 피라진아미드 시장 성장을 촉진하는 요인에는 세계의 결핵 부담 증가를 들 수 있습니다. 미국 질병 예방 관리 센터에 의하면, 2017년 전세계에서 1,000만명이 결핵을 앓았으며, 130만명의 결핵 관련 사망자가 발생했습니다.

2018년에 발표된 WHO 데이터에 의하면, 결핵에 의한 지출은 치료와 예방에 92억 달러, 추가 경제적 비용과 생산성 손실이 120억 달러에 달했으며, 매년 210억 달러 이상에 이르고 있습니다. 이로 인해 결핵 치료를 위한 헬스케어비 증가가 시장 성장을 촉진할 것으로 예상되고 있습니다.

세계의 피라진아미드(Pyrazinamide) 시장에 대해 조사했으며, 시장 기회와 동향, 성장 촉진요인 및 억제요인, 환자 유형·유통채널·지역별 시장 분석, 경쟁 구도, 주요 기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 조사 목적과 전제조건

제2장 시장 개요

  • 보고서 개요
    • 시장의 정의와 범위
  • 개요
    • 환자 유형별
    • 유통채널별
    • 지역별
  • Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

  • 시장 역학
    • 성장요인
    • 억제요인
    • 시장 기회
  • 시장 동향
  • 주요 발전
  • 영향 분석
  • 인수합병(M&A)
  • 신제품 발매
  • 기술 개요
  • PEST 분석

제4장 COVID-19 팬데믹의 영향

  • COVID-19의 영향 분석
  • 새로운 개발

제5장 시장 분석 : 환자 유형별(2016-2027년)

  • 서론
  • 성인
  • 소아

제6장 시장 분석 : 유통채널별(2016-2027년)

  • 서론
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제7장 시장 분석 : 지역별(2016-2027년)

  • 서론
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동
  • 아프리카

제8장 경쟁 구도

  • 기업 개요
    • Pure Chemistry Scientific
    • LGM Pharma
    • City Chemical
    • TCI
    • HBCChem
    • Alfa Chemistry
    • Toronto Research Chemicals
    • Acros Organics
    • AlliChem
    • Waterstone Technology

제9장 섹션

LSH 21.01.14

Title:
Pyrazinamide Market, by Patient Type (Adult and Pediatric), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Pyrazinamide (PZA) is a medication used to treat tuberculosis. Moreover, for active tuberculosis, it is often used with rifampicin, isoniazid, and either streptomycin or ethambutol. It is not generally recommended for the treatment of latent tuberculosis. Pyrazinamide kills non-replicating persister cells that other medication of TB fail to kill, and for which it became important drug for inclusion in any drug combinations for treating drug susceptible and drug-resistant TB such as MDR-TB. It acts variably compared to other antibiotics by inhibiting energy production, trans-translation, and co-enzyme A required for persister survival. The increasing mutation in drug targeted gene is marking bacterial strain more resistant to PZA drug. The recently panD mutations gene was found along with pncA or rpsA mutations gene in bacterial resistant strains.

Market Dynamics

The high burden of TB is expected to drive growth of the market. For instance, according to the WHO, in 2017, 87% of new TB cases occurred in 30 high TB burden countries. The eight countries out of 30 include India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa, which accounted for two thirds of the new TB cases.

The increasing global burden of TB is expected to drive the pyrazinamide market growth. For instance, according to the Centre for Disease Control and Prevention, in 2017, 10.0 million people around the world suffered from TB, and there were 1.3 million TB-related deaths worldwide.

Moreover, according to the WHO data published in 2018, TB costs the world over US$ 21 billion each year, including US$ 9.2 billion for treatment and prevention, and US$ 12 billion in additional economic costs and lost productivity. Thus, increasing healthcare spending on treatment of TB is expected to drive growth of the market.

Moreover, according to the WHO, treatment for multi-drug resistant TB (MDR-TB) takes 20-26 months, and average cost of treatment in the U.S. is around US$ 294,000.

Moreover, increasing investments in R&D activities for development of novel therapies for treatment of TB is expected to restrain growth of the pyrazinamide drugs market. For instance, according to the Tuberculosis Research Funding Trends 2005-2017 reports, global investment in TB research was valued at US$ 772 Million in 2017, with an increase of 6% (or US$ 46 million), compared to US$ 726 million in 2016.

Key features of the study:

  • This report provides in-depth analysis of the global pyrazinamide market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
  • It profiles key players in the global pyrazinamide market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Pure Chemistry Scientific, LGM Pharma, TCI, HBCChem, Alfa Chemistry, Toronto Research Chemicals, Acros Organics, AlliChem, Waterstone Technology, City Chemical, EDQM, J & K SCIENTIFIC, Meryer (Shanghai) Chemical Technology, Energy Chemical, and Beijing Ouhe Technology.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global pyrazinamide market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers of Infertility drugs and devices, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Pyrazinamide Market, By Patient Type:
    • Adult
    • Pediatric
  • Global Pyrazinamide Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Pyrazinamide Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Patient Type:
    • Adult
    • Pediatric
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Patient Type:
    • Adult
    • Pediatric
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Patient Type:
    • Adult
    • Pediatric
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Patient Type:
    • Adult
    • Pediatric
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Patient Type:
    • Adult
    • Pediatric
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
      • By Patient Type:
    • Adult
    • Pediatric
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Company Profiles
      • Pure Chemistry Scientific*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
      • LGM Pharma
      • City Chemical
      • TCI
      • HBCChem
      • Alfa Chemistry
      • Toronto Research Chemicals
      • Acros Organics
      • AlliChem
      • Waterstone Technology

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Patient Type
    • Market Snapshot, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Market Trends
  • Key Developments
  • Impact Analysis
  • Mergers & Acquisitions
  • New Product Launch
  • Technology Overview
  • PEST Analysis

4. Global Pyrazinamide Market - Impact of Coronavirus (Covid-19) Pandemic

  • COVID 19 Impact Analysis
  • New Developments

5. Global Pyrazinamide Market, By Patient Type, 2016 - 2027, (US$ million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Pyrazinamide Market, By Distribution Channel, 2016 - 2027, (US$ million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Pyrazinamide Market, By Region, 2016- 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
    • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2027
    • Regional Trends
  • North America
    • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
    • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
    • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
    • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
    • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East
    • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
    • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Share Analysis, By Patient Type, 2020 and 2027 (%)
    • Market Share Analysis, By Distribution Channel, 2020 and 2027 (%)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

  • Company Profiles
    • Pure Chemistry Scientific
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • LGM Pharma
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • City Chemical
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • TCI
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • HBCChem
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Alfa Chemistry
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Toronto Research Chemicals
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Acros Organics
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • AlliChem
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Waterstone Technology
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top
전화 문의
F A Q